Advertisement

Topics

Tyrogenex Company Profile

11:55 EDT 21st June 2018 | BioPortfolio

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.


News Articles [1 Associated News Articles listed on BioPortfolio]

Tyrogenex Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15032018] Prices from USD $250

SummaryTyrogenex Inc Tyrogenex is a biopharmaceutical company that develops next generation targeted therapeutics for cancer. The company develops dual vascular endothelial growth factor receptor and ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolera...

Xcovery

Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, PhD, Xcoveryâ€...

More Information about "Tyrogenex" on BioPortfolio

We have published hundreds of Tyrogenex news stories on BioPortfolio along with dozens of Tyrogenex Clinical Trials and PubMed Articles about Tyrogenex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tyrogenex Companies in our database. You can also find out about relevant Tyrogenex Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record